Black box warning from FDA for ‘diabetic foot jell’ Regranex

Johnson & Johnson’s Regranex, a prescription foot jell which is used to treat refractory leg and foot ulcers in patients with diabetes, is now being given the black box warning from the US FDA.

The updated warning states that patients who use three or more tubes of the gel over two years are five times more likely to die from cancer than those who do not use it. The label also advises physicians to use caution when prescribing the drug to patients with malignancies.